Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (1)
P 1 (9)
P 2 (10)
P 3 (3)

Trial Status

Unknown10
Recruiting6
Completed4
Active Not Recruiting3
Not Yet Recruiting2
Terminated2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT04704661Phase 1Active Not Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT05969860Phase 2Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT04491942Phase 1Active Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT06264921Phase 1Terminated

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

NCT06028737Phase 2Recruiting

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

NCT06666166Phase 2Not Yet RecruitingPrimary

SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

NCT06642857RecruitingPrimary

Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.

NCT04535401Phase 1Active Not Recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

NCT04808791Phase 2Completed

iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04718402Phase 1TerminatedPrimary

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

NCT05226169Phase 3RecruitingPrimary

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

NCT05997524Phase 2CompletedPrimary

Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.

NCT05805956Phase 1Unknown

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

NCT05620732Not ApplicableRecruiting

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

NCT05334849CompletedPrimary

Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy

NCT05545293UnknownPrimary

Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers

NCT05351398UnknownPrimary

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer

NCT05313906Phase 2UnknownPrimary

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

NCT05270824Phase 3Not Yet RecruitingPrimary

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

Scroll to load more

Research Network

Activity Timeline